Table 3.

Adjusted odds ratios for the risk of the outcomes with proton pump inhibitor use (vs. non-use) and H2RA use (vs. non-use) among clopidogrel users at 3-, 6-, and 12-month follow-up

Endpoint and follow-up	Matched cases/controls	Unmatched cases	PPI use vs. non-use, OR (95% CI)	H2RA use vs. non-use (negative control), OR (95% CI)
MI
3 months	1569/7573	24	1.08 (0.95–1.23)	0.88 (0.76–1.02)
6 months	2220/10,684	32	1.05 (0.95–1.17)	0.9 (0.81–1.03)
12 months	2890/13,933	42	1.0 5 (0.96–1.15)	0.9 3 (0.84–1.04)
In-hospital mortality
3 months	1418/6845	22	1.13 (0.98–1.29)	1.05 (0.91–1.22)
6 months	1933/9348	28	1.11 (0.99–1.24)	1.01 (0.89–1.15)
12 months	2596/12,551	39	1.04 (0.95–1.15)	0.93 (0.83–1.04)
Stroke
3 months	764/3717	6	0.92 (0.77–1.10)	0.87 (0.71–1.06)
6 months	1101/5377	8	0.9 6 (0.83–1.12)	0.86 (0.73–1.02)
12 months	1536/7510	15	0.96 (0.85–1.08)	0.84 (0.73–0.97)
Composite endpoint
3 months	3493/16,902	52	1.07 (0.99–1.17)	0.95 (0.87–1.05)
6 months	4838/23,384	67	1.06 (0.99–1.14)	0.96 (0.88–1.03)
12 months	6403/30,957	90	1.04 (0.98–1.11)	0.93 (0.87–1.00)

CI confidence interval, H2RA H2 receptor antagonist, MI myocardial infarction, OR odds ratio